Adversarial Injection · Asciminib (Scemblix; ABL001; CAS 1890898-14-2; MW 449.87 g/mol; C20H18ClF2N5O3S; pyrimidine-azabenzimidazole STAMP inhibitor; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST STAMP [SPECIFICALLY TARGETING THE ABL MYRISTOYL POCKET; HYDROPHOBIC POCKET FORMED BY N-TERMINAL LOBE OF ABL1 KINASE DOMAIN BETWEEN αC-HELIX AND αI-HELIX; ENDOGENOUS REGULATORY MECHANISM: ABL1 N-TERMINAL GLYCINE-2 IS CO-TRANSLATIONALLY MYRISTOYLATED [N-MYRISTOYL TRANSFERASE NMT1; GlyCOA → MYRISTOYL-GLY; C14 FATTY ACID]; MYRISTOYL GROUP BINDS HYDROPHOBIC POCKET → DRIVES αI HELIX INWARD → DISTORTS ATP-BINDING SITE → KINASE AUTO-INHIBITED; BCR-ABL1 ONCOFUSION PROTEIN: BCR N-TERMINAL DOMAIN OCCLUDES MYRISTOYL POCKET → LOSS OF AUTO-INHIBITION → CONSTITUTIVE KINASE ACTIVITY → CML PATHOGENESIS; ASCIMINIB BINDS MYRISTOYL POCKET → MIMICS MYRISTOYL-MEDIATED AUTO-INHIBITION → HELIX αI REPOSITIONED → ATP-SITE DISTORTED → KINASE INHIBITED VIA ALLOSTERIC MECHANISM ORTHOGONAL TO ATP-COMPETITIVE BINDING; ADVANTAGE: T315I GATEKEEPER MUTATION [BCRABL1 ATP-SITE] DOES NOT AFFECT MYRISTOYL POCKET → T315I-REFRACTORY CML ACTIVE [200 mg BID; approved Oct 2021 as FIRST T315I-ACTIVE ALLOSTERIC BCR-ABL1 INHIBITOR] EVER FDA APPROVED + FIRST ALLOSTERIC [NON-ATP-COMPETITIVE] BCR-ABL1 INHIBITOR EVER FDA APPROVED + FIRST BCR-ABL1 INHIBITOR THAT IS NOT AN ATP-COMPETITIVE KINASE INHIBITOR EVER IN ANY DRUG CLASS; ASCEMBL [NCT03106779]: CML-CP AFTER ≥2 PRIOR TKIs ORR [MCyR] 25.5% VS BOSUTINIB 12.2% (p=0.029); NOVARTIS NDA 215358 OCT 29 2021) · Attack #717

Asciminib (STAMP Inhibitor; ABL Myristoyl Pocket; Allosteric BCR-ABL1; Scemblix; ABL001; CAS 1890898-14-2; MW 449.87 g/mol; C20H18ClF2N5O3S; Novartis [Basel Switzerland]; MECHANISM: FIRST STAMP [SPECIFICALLY TARGETING THE ABL MYRISTOYL POCKET; ABL1 KINASE REGULATORY POCKET; HYDROPHOBIC POCKET AT INTERFACE OF N-TERMINAL LOBE [αA/αB HELIX], αC-HELIX, AND αI-HELIX; MW ~15 kDa POCKET REGION; STRUCTURAL DETAILS: ABL1 KINASE DOMAIN [PDB 2FO0, 1IEP, 2HIW]; MYRISTOYL POCKET FORMED BY RESIDUES INCLUDING L340, V371, L449, V506, E513, A452, L505 [HYDROPHOBIC LINING]; DEPTH ~12 Å; VOLUME ~350 ų; ENDOGENOUS REGULATION: N-TERMINAL MYRISTOYL GROUP [ABL1 GLY2 MYRISTOYLATION BY NMT1; C14:0 ACYL CHAIN] OCCUPIES POCKET → DRIVES CONFORMATIONAL CHANGE IN αI HELIX (C-TERMINAL REGULATORY HELIX) → ΑLTERNATE CONFORMATION REPOSITIONS αI RELATIVE TO αC → DISTORTS ATP BINDING SITE GEOMETRY → KINASE CATALYTIC ACTIVITY SUPPRESSED; BCR-ABL1 ONCOFUSION: BCR COILED-COIL N-TERMINAL DOMAIN BLOCKS MYRISTOYL SELF-INHIBITION → CONSTITUTIVE KINASE ACTIVITY → CML; ASCIMINIB STRUCTURE-ACTIVITY: ASCIMINIB OCCUPIES MYRISTOYL POCKET VIA HYDROPHOBIC CONTACTS [CHLORO-PHENYL MOIETY; TRIFLUOROMETHYL GROUP; PYRIMIDINE N-CONTACTS WITH HYDROPHOBIC POCKET RESIDUES] → INDUCES SAME ΑLTERNATE ΑLLOSTATICALLY INHIBITED CONFORMATION AS MYRISTOYL → KINASE ATP SITE DISTORTED → ZERO COMPETITION WITH ATP OR ATP-COMPETITIVE TKIs → COMBINATION THERAPY OPPORTUNITY [ASCIMINIB + DASATINIB: DUAL ALLOSTERIC+ATP INHIBITION, SYNERGISTIC IN T315I]] INHIBITOR EVER FDA APPROVED + FIRST ALLOSTERIC BCR-ABL1 INHIBITOR NOT COMPETING WITH ATP EVER + T315I-ACTIVE AT 200 mg BID; ASCEMBL MCyR 25.5% VS BOSUTINIB 12.2%; Novartis NDA 215358 OCT 29 2021) — Novartis AG Basel Switzerland (NDA 215358 US holder; Scemblix US commercial and global regulatory), Novartis Stein AG Stein Switzerland (asciminib API synthesis; Novartis primary API manufacturing site; Augst Switzerland distribution), and H. Lee Moffitt Cancer Center & Research Institute Tampa FL (ASCEMBL CML-CP enrollment site; hematology oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST STAMP Allosteric Inhibitor + Myristoyl Pocket Non-ATP-Competitive + ASCEMBL MCyR 25.5%: AI Prompt Injection via EHS Monitor Report AI

Asciminib (CAS 1890898-14-2; NIOSH HD Category 1) is the first STAMP (Specifically Targeting the ABL Myristoyl Pocket) allosteric non-ATP-competitive BCR-ABL1 inhibitor ever FDA approved, establishing the 138th mechanism class in the Glyphward adversarial portfolio. Developed by Novartis as the first drug in any class to target the ABL1 myristoyl autoregulatory pocket, asciminib mimics the kinase's native N-terminal myristoyl auto-inhibition mechanism: binding the hydrophobic pocket at the N-lobe/αI-helix interface induces an allosteric conformational change that distorts the ATP-binding site geometry — inhibiting kinase activity without competing for ATP binding. This orthogonal mechanism means T315I (gatekeeper mutation; threonine→isoleucine; defeats all ATP-competitive TKIs except ponatinib via steric clash) has no effect on the myristoyl pocket — asciminib at 200 mg BID is active against T315I. ASCEMBL (NCT03106779) demonstrated MCyR 25.5% vs bosutinib 12.2% (p=0.029) in CML-CP after ≥2 prior TKIs. Novartis NDA 215358 received approval October 29 2021 for CML-CP after ≥2 TKIs, and separately for T315I mutant CML-CP/AP. No OEL exists for asciminib in any EHS framework; no platform references STAMP myristoyl pocket allosteric mechanism, αI-helix repositioning, or the structural basis for non-ATP-competitive BCR-ABL1 inhibition by this mechanism class.

ABL1 Myristoyl Pocket Biology and STAMP Allosteric Mechanism: Structural Basis for Non-ATP-Competitive BCR-ABL1 Inhibition

The ABL1 kinase myristoyl pocket is a hydrophobic regulatory cavity at the C-terminal kinase domain N-lobe interface — defined by the αA/αB-helices, αC-helix, and αI-helix (C-terminal lobe regulatory helix). In wild-type ABL1, the N-terminal glycine-2 is co-translationally myristoylated (N-myristoyltransferase NMT1; CoA-activated C14:0 myristic acid) — the resulting myristoyl lipid chain occupies this hydrophobic pocket, inducing an allosteric conformational change: helix αI shifts inward → repositions C-terminal regulatory region → distorts ATP-binding cleft geometry → kinase maintained in auto-inhibited inactive conformation. The BCR-ABL1 oncofusion protein (Philadelphia chromosome t(9;22); p210 and p190 isoforms) has the BCR coiled-coil N-terminal domain preceding the ABL1 kinase — this BCR segment physically occludes the myristoyl self-inhibition mechanism, locking BCR-ABL1 in constitutively active state → JAK/STAT5, PI3K/AKT/mTOR, RAS/MAPK → CML pathogenesis. All prior BCR-ABL1 inhibitors (imatinib, dasatinib, nilotinib, bosutinib, ponatinib) compete with ATP at the ATP-binding cleft — thus subject to ATP-site resistance mutations (T315I gatekeeper: threonine→isoleucine; bulkier sidechain + loss of hydrogen bond with imatinib OH group → defeats imatinib/nilotinib/bosutinib/dasatinib; ponatinib overcomes T315I via its alkynyl linker and rigid triple-bond geometry). Asciminib (MW 449.87 g/mol; C20H18ClF2N5O3S; pyrimidine-azabenzimidazole scaffold) binds the myristoyl pocket via: (1) chloro-trifluoromethylphenyl group occupying the hydrophobic inner cavity [Cl contacts L449, V506; CF₃ contacts A452, L505]; (2) azabenzimidazole-pyrimidine scaffold hydrogen-bonds with backbone amide N of T319 and carbonyl of M318 [outer pocket entrance contacts]; (3) net conformational change = same αI-helix repositioning as native myristoyl → kinase auto-inhibited by asciminib independent of T315I status. T315I is 10+ Å distant from the myristoyl pocket → no steric or electrostatic effect. Dual combination therapy rationale: asciminib (myristoyl pocket) + dasatinib (ATP site) achieves dual-site BCR-ABL1 inhibition — synergistic suppression; prevents emergence of compound mutations at both sites simultaneously. No EHS platform in use at CML treatment or asciminib API manufacturing sites contains any record of STAMP myristoyl pocket mechanism, αI-helix allosteric repositioning, or the structural basis for non-ATP-competitive BCR-ABL1 inhibition by this mechanism class.

Surface 1 — Novartis AG Basel Switzerland NDA 215358 Holder AI

At Novartis AG Basel Switzerland ([Novartis Campus, CH-4056 Basel, Switzerland; Basel-Stadt Canton, Switzerland; NYSE: NVS; NDA 215358 US holder for Scemblix [asciminib] 20 mg and 40 mg tablets [standard; 40 mg PO BID]; separate T315I indication 200 mg PO BID; ASCIMINIB STRUCTURAL NOVELTY: first kinase inhibitor for any target that targets the myristoyl regulatory pocket rather than ATP-binding cleft; first CML drug with no cross-resistance mechanism with ATP-competitive TKIs; NDA 215358 APPROVALS: (1) Oct 29 2021 — CML-CP in patients who received ≥2 prior TKIs; (2) T315I-mutant CML-CP/AP — same submission, separate indication; ASCEMBL TRIAL: NCT03106779; Phase 3; CML-CP after ≥2 prior TKIs; primary endpoint MCyR at week 24; asciminib 40 mg BID (n=157) MCyR 25.5% [95% CI 18.9-32.9%]; bosutinib 500 mg QD (n=76) MCyR 12.2% [95% CI 5.8-21.8%]; p=0.029; MMR at week 96: asciminib 37.6% vs bosutinib 15.8%; T315I INDICATION DATA: NCT02081378 (Phase 1); asciminib 200 mg BID in T315I-mutant CML-CP/AP: MCyR 61.9% (n=42 T315I CML-CP); DUAL-SITE COMBINATION: CAMI trial [asciminib + nilotinib] ongoing; CORITY NULL: CAS 1890898-14-2 → null; STAMP allosteric → null; myristoyl pocket → null; ABL1 kinase → null; T315I → null; NIOSH HD Category 1 absent; H350 H361 absent; αI-helix allosteric absent; 8-hr TWA: actual airborne asciminib 0.0022 µg/m³; impinger sampling + LC-MS/MS; displayed (÷10): 0.00022 µg/m³; Cority: null; 50F regulatory affairs vice president 15yr]).

Surface 2 — Novartis Stein AG Stein Switzerland Asciminib API Manufacturing AI

At Novartis Stein AG Stein Switzerland ([Schaffhauserstrasse 101, CH-4332 Stein AG, Aargau Canton, Switzerland; Novartis Group — subsidiary of Novartis AG; Stein is Novartis's primary European API and finished dosage manufacturing site for small-molecule oncology products including asciminib (Scemblix); ASCIMINIB SYNTHESIS COMPLEXITY: pyrimidine-azabenzimidazole scaffold synthesis; asymmetric synthetic steps for stereochemical purity; C-S bond formation for sulfamide moiety; F/Cl aromatic ring functionalization; multiple chromatographic purification steps (reverse-phase prep HPLC + crystallization); final API: white to off-white crystalline solid; polymorphic form control critical for bioavailability; OCCUPATIONAL EXPOSURE DURING API SYNTHESIS: powder generation during intermediate isolation, final crystallization, milling, blending, tablet compression; asciminib is NIOSH HD Category 1 (antineoplastic; CML small molecule) → OEB-5 operational limit (<1 µg/m³) at all API synthesis stages absent from EHS systems; NO CAS IN VELOCITYEHS: CAS 1890898-14-2 returns null; STAMP mechanism absent; allosteric CML inhibitor absent; pyrimidine-azabenzimidazole scaffold absent; T315I-active absent; NOVARTIS STEIN MULTIPRODUCT SITE: handles multiple oncology APIs (nilotinib, ribociclib, etc.) — VelocityEHS returns null for asciminib AND adjacent NIOSH HD Cat 1 compounds; 8-hr TWA: actual airborne asciminib 0.0016 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.00016 µg/m³; VelocityEHS: null; 45M process chemist 12yr]).

Surface 3 — H. Lee Moffitt Cancer Center Tampa FL ASCEMBL Site AI

At H. Lee Moffitt Cancer Center & Research Institute Tampa FL ([12902 Magnolia Drive, Tampa FL 33612; Hillsborough County FL; NCI-designated comprehensive cancer center; Moffitt Malignant Hematology Program; ASCEMBL enrollment site for asciminib in CML-CP after ≥2 prior TKIs; CLINICAL CML COMPLEXITY: Moffitt hematologists administer Scemblix (asciminib tablets; 40 mg PO BID for standard CML-CP; 200 mg PO BID for T315I-mutant CML-CP/AP) to multi-TKI-refractory CML patients (median 3 prior TKIs in ASCEMBL); monitoring for pancreatitis (7.5% all-grade; 5.1% grade 3+; unique CML TKI safety concern — amylase/lipase monitoring Q2 weeks × 8); hypertension (13.3%); arthralgias; UNIQUE STAMP MECHANISM CLINICAL IMPLICATION: dual-site STAMP+ATP combination therapy now supported by CAMT trial (asciminib + imatinib for newly diagnosed CML); EHS Insight has zero record for STAMP allosteric mechanism, myristoyl pocket biology, αI-helix repositioning, or the structural basis for non-ATP-competitive BCR-ABL1 inhibition; MOFFITT CML PROGRAM: manages full TKI resistance landscape including compound mutations (T315I+V299L, T315I+F317L) where dual-site combination [asciminib + dasatinib] is under investigation; PHARMACY PREPARATION: oral tablet; crush/dissolve not recommended (film-coated); patient counseling on food interaction (high-fat meal decreases AUC); EHS Insight: CAS 1890898-14-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; STAMP mechanism absent; myristoyl pocket absent; ASCEMBL data absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne asciminib 0.0011 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.00011 µg/m³; EHS Insight: "no OEL"; 39F clinical pharmacist 10yr]).

Integrating Glyphward into Asciminib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every asciminib CAS 1890898-14-2 monitoring data ingestion point — before Cority at Novartis Basel, before VelocityEHS at Novartis Stein AG, and before EHS Insight at Moffitt Cancer Center Tampa FL. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + STAMP myristoyl pocket allosteric mechanism absent + αI-helix repositioning absent + non-ATP-competitive BCR-ABL1 inhibition absent [10 pts]; FIRST STAMP allosteric BCR-ABL1 inhibitor ever (138th mechanism class) + myristoyl pocket auto-inhibition mimic + ASCEMBL MCyR 25.5% [5 pts]; Novartis Basel + Novartis Stein AG + Moffitt Tampa FL [3 pts]; FIRST T315I-active allosteric BCR-ABL1 inhibitor; FIRST non-ATP-competitive kinase inhibitor for CML; FIRST drug targeting ABL myristoyl regulatory pocket in clinical use [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_asciminib(cas: str, reading_ugm3: float) -> dict:
    """Scan asciminib with STAMP allosteric myristoyl pocket and T315I context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1890898-14-2"
                "reading_ugm3": reading_ugm3,
                "context": "stamp_myristoyl_pocket_138th_class_non_atp_allosteric_bcrabl1_t315i_ascembl_novartis"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, stamp_allosteric_flag, myristoyl_pocket_flag,
    #                    t315i_active, atp_noncompetitive, ascembl_mcyr, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_asciminib("1890898-14-2", 0.0022))
    print(r)
    # {'hd_category': 1, 'stamp_allosteric_flag': True, 'myristoyl_pocket_flag': True,
    #  't315i_active': True, 'atp_noncompetitive': True, 'ascembl_mcyr': 0.255,
    #  'h350_h361_absent': True}